{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:53Z","timestamp":1786988153998,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejps.2024.106979","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T21:33:04Z","timestamp":1733347984000},"page":"106979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-7555","authenticated-orcid":false,"given":"Natalja","family":"Bouwhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliene M.","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma A.","family":"Bijleveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Giera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Heijink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric M.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert H.","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureen A. ten","family":"Berg-Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje E.L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A.W.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Marleen","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106979_bib0001","unstructured":"Arzneibuch-Kommentar (2004). Kommental zur Ph.Eur. 4.00."},{"key":"10.1016\/j.ejps.2024.106979_bib0002","unstructured":"EDQM (2017). Archives of the European pharmacopoeia, edition 9.0, monograph chenodeoxycholic acid 01\/2017:1189."},{"key":"10.1016\/j.ejps.2024.106979_bib0003","series-title":"Pharmeuropa 31.3: Draft Monograph 1189","year":"2019"},{"key":"10.1016\/j.ejps.2024.106979_bib0004","unstructured":"EDQM (2019b). European Pharmacopoeia, Edition 10.0, Chapter 5.10: control of impurities in substances for pharmaceutical use."},{"key":"10.1016\/j.ejps.2024.106979_bib0005","unstructured":"EDQM (2021). European Pharmacopoeia, Supplement 10.3, Monograph Substances for pharmaceutical use 01\/2021:2034."},{"key":"10.1016\/j.ejps.2024.106979_bib0006","unstructured":"EDQM (2022). European pharmacopoeia, supplement 10.6, monograph chenodeoxycholic acid 01\/2022:1189."},{"key":"10.1016\/j.ejps.2024.106979_bib0007","volume":"4","year":"2014"},{"key":"10.1016\/j.ejps.2024.106979_bib0008","unstructured":"European Commission (2015). Guidelines on principles of good distribution practice of active substances for medicinal products for human use."},{"key":"#cr-split#-10.1016\/j.ejps.2024.106979_bib0009.1","unstructured":"European Parliament and Council of the European Union (2017). Commission directive"},{"key":"#cr-split#-10.1016\/j.ejps.2024.106979_bib0009.2","unstructured":"(EU) 2017\/1572 of 15 September 2017 supplementing directive 2001\/83\/EC of the European parliament and of the council as regards the principles and guidelines of good manufacturing practice for medicinal products for human use."},{"key":"10.1016\/j.ejps.2024.106979_bib0010","unstructured":"European Parliament and Council of the European Union (2022). Directive 2001\/83\/EC of the european parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use."},{"key":"10.1016\/j.ejps.2024.106979_bib0011","series-title":"GeneReviews\u00ae [Internet]","first-page":"1993","article-title":"Cerebrotendinous xanthomatosis","author":"Federico","year":"2003"},{"key":"10.1016\/j.ejps.2024.106979_bib0012","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejps.2024.106979_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.758210","article-title":"Pharmacy compounded medicines for patients with rare diseases: lessons learned from chenodeoxycholic acid and cholic acid","volume":"12","author":"Polak","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejps.2024.106979_bib0014","doi-asserted-by":"crossref","first-page":"k5127","DOI":"10.1136\/bmj.k5127","article-title":"Dutch hospital's manufacture of drug for rare condition was legal, says inspectorate","volume":"363","author":"Sheldon","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.ejps.2024.106979_bib0015","doi-asserted-by":"crossref","first-page":"k2103","DOI":"10.1136\/bmj.k2103","article-title":"Dutch hospital makes own drug for rare condition after manufacturer hikes price to \u20ac170\u2009000","volume":"361","author":"Sheldon","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.ejps.2024.106979_bib0016","doi-asserted-by":"crossref","first-page":"m401","DOI":"10.1136\/bmj.m401","article-title":"Dutch hospital resumes production of rare drug after sourcing purer ingredients","volume":"368","author":"Sheldon","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ejps.2024.106979_bib0017","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1212\/WNL.0000000000006731","article-title":"Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start","volume":"92","author":"Stelten","year":"2019","journal-title":"Neurology"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:20:06Z","timestamp":1736590806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724002926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":18,"alternative-id":["S0928098724002926"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106979","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the identification and quantification of an unknown impurity in chenodeoxycholic acid drug substance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106979"}}